Inducing MiR-137 Offers Protection in Pancreatic Cancer

Pancreatic tumors often lose the ability to express a small ribonucleic acid molecule called miR-137 which induces a defence mechanism against cancer cells.

Pancreatic cancer, the molecular mechanisms that cause this cancer to develop has now been a recent breakthrough by two research teams, including one at the Maisonneuve-Rosemont (CIUSSS-EST, Montreal) and University of Montreal.

This //biomedical research conducted jointly by the groups of Dr. Fredrick Antoine Mallette and Dr. Stephane Richard (McGill University / Lady Davis Institute for Medical Research) has shown that pancreatic tumors often lose the ability to express a small ribonucleic acid molecule called miR-137. This molecule induces a defence mechanism called cellular senescence, which keeps cancer cells in check. The loss of miR-137 works in conjunction with various mutations frequently observed in pancreatic tumours to trigger uncontrolled cell growth and then cancer.

Pancreatic Cancer - All About the Disease, its Diagnosis and Management
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.

‘Restoring normal miR-137 (a ribonucleic acid), in pancreatic cancer cells has a protective effect, as it induces the defense mechanism and stops the cells from spreading.’

"It is essential that we better understand the mechanisms that lead to the loss of miR-137 expression. Once we do, we can create therapeutic strategies to treat and prevent pancreatic cancer," said Dr. Fredrick Antoine Mallette.

This joint research study by doctoral student Mathieu Neault has also demonstrated that restoring normal miR-137 levels in pancreatic cancer cells has a protective effect, as doing so induces senescence and stops the cells from spreading.

A relentless cancer

Pancreas Transplantation - Procedure, Evaluation, Preparation, Surgery, After care
Pancreas transplant is a surgical procedure involving the replacement of a dysfunctional pancreas in a person with Type 1 or insulin-dependent diabetes.
In 2015, approximately 4800 people received a diagnosis of pancreatic cancer, and nearly 4600 Canadians succumbed to this terrifying disease. Although this cancer is the 12th highest in terms of incidence, it is 4th highest in cancer-related mortality. Survival rates for pancreatic cancer haven't improved in the past 40 years. This is why we urgently need to clarify the mechanisms of this cancer to find new therapeutic avenues that will change these grim statistics.

New Effective Artificial Pancreas to Improve the Life of Type 1 Diabetics
A randomized controlled study was conducted for establishing the efficacy of artificial pancreas over conventional insulin therapy in type I diabetes adults, and control of nocturnal hypoglycemia

Source-Eurekalert

New Method That Lets an Earlier Diagnosis of Pancreatic Cancer Developed
Researchers have devised a new method than allows an earlier diagnosis of pancreatic cancer.